LYEL — Lyell Immunopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1806952 ·
Last close
$13.67
Market Cap
$336.08M
52W High
$45.00
52W Low
$7.20
ADV30
229,490
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 3,000 | — | -48,295,000 | -45,529,000 | 273,854,000 | 92,053,000 | 81,133,000 |
| Jun 2026 | 4,000 | — | -47,337,000 | -44,755,000 | 311,153,000 | 72,985,000 | 77,338,000 |
| Mar 2026 | 2,000 | — | -44,261,000 | -24,153,000 | 350,626,000 | 90,770,000 | 76,961,000 |
| Dec 2025 | 6,000 | — | -61,312,000 | -140,723,000 | 340,052,000 | 60,181,000 | 91,850,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-139,250,000
Investing CF
$55,223,000
Financing CF
$52,507,000
CapEx
$-715,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-11.50
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,733,991,000
Inventory
—
Receivables
—
ST Investments
$85,053,000
EBIT TTM
$-201,205,000
Pretax Income TTM
$-255,160,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,000
EBITDA
$-192,248,992
Free Cash Flow
$-65,903,752
Enterprise Value
$232,520,496
Total Cash
$177,106,000
Total Debt
$44,285,000
Shares Out
24,585,565
Trailing EPS
$-12.61
Book Value
$7.84
ROE
-97.8%
ROA
-36.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 36,000 | -201,629,000 | -274,448,000 | 340,052,000 | 91,850,000 | 248,202,000 | -150,024,000 |
| Dec 2024 | 61,000 | -220,274,000 | -342,994,000 | 490,859,000 | 108,035,000 | 382,824,000 | -162,394,000 |
| Dec 2023 | 130,000 | -247,008,000 | -234,632,000 | 750,029,000 | 95,077,000 | 654,952,000 | -163,694,000 |
| Dec 2022 | 84,683,000 | -187,058,000 | -183,118,000 | 937,561,000 | 104,309,000 | 833,252,000 | -169,555,000 |
TTM Snapshot
Revenues TTM
$27,000
NetIncome TTM
$-248,477,000
OpCashFlow TTM
—
Assets (Latest)
$311,153,000
Forward EPS
$-6.32
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $16.00 · spot: $13.89 · call volume: 191 · put volume: 35
Expected Move to 2027-01-15:
±$4.16
(29.95%) —
implied range
$9.73 –
$18.05
· ATM straddle on $14.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | $337.62M | $9.55 | — |
| VREOF | Vireo Growth Inc. | $346.76M | $6.01 | — |
| ASPE | Aspen Neuroscience, Inc. | $348.94M | $12.00 | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $321.15M | $3.01 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $318.00M | $3.96 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts See a 148.25% Upside in Lyell Immunopharma (LYEL): Can the Stock Really Move This High?
2026-11-16 13:55 · Yahoo
Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy
2026-11-06 08:14 · Yahoo
Lyell Immunopharma: Q3 Earnings Snapshot
2026-11-04 22:24 · Yahoo
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
2026-11-04 21:05 · Yahoo
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
2026-11-04 14:02 · Yahoo
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory L
2026-11-04 14:01 · Yahoo
Lyell Immunopharma To Participate in November Investor Events
2026-11-02 13:00 · Yahoo
Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
2026-10-13 12:35 · Yahoo
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
2026-09-10 20:05 · Yahoo
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
2026-07-02 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.